tepotinib (Tepmetko)
Jump to navigation
Jump to search
Indications
- metastatic non-small cell lung cancer harboring MET exon-14 skipping alterations
Dosage
- 450 mg orally once daily with food
225 MG Oral Tablet
Adverse effects
- most common (> 20%
- less common (> 2%)
- lymphopenia, hypoalbuminemia, hyponatremia, increased gamma-glutamyltransferase, increased amylase, elevated serum transaminases, anemia
- serious:
- interstitial lung disease, hepatotoxicity, embryo-fetal toxicity
Mechanism of action
- kinase inhibitor that targets met-proto-oncogene protein
More general terms
References
- ↑ RxNorm
- ↑ FDA Approval, DFeb 3, 2021 FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-tepotinib-metastatic-non-small-cell-lung-cancer
- ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION TEPMETKO<TM> (tepotinib) tablets, for oral use https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf